Nat. Rev. Rheumatol. doi: /nrrheum

Slides:

Advertisements

Similar presentations

Mechanism and New. Lupus Erythematosus - Medication NSAIDs may be used for musculoskeletal and mild systemic complaints, although ibuprofen.

Advertisements

Systemic lupus erythematous with lupus nephritis Diagnosis & Treatment

“Monitoring Systemic Lupus Erythematosus” Andres Quiceno, MD Presbyterian Hospital of Dallas.

Lupus Nephritis Treatment

Detection of Renal Hypoxia in Lupus Nephritis Using Blood Oxygen Level-Dependent MR Imaging: A Multiple Correspondence Analysis Kidney Blood Press Res.

Number of Grafts Performed by Country

FIGURE 1 Trial profile. The safety population was defined as all randomly assigned patients who received at least one dose of study drug. All patients.

Figure 3 The induction of anti-DNA antibodies by bacterial DNA

Joint European League Against Rheumatism and European Renal Association–European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for.

Effects of MMF treatment in patients with SLE

Please note this program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States.

Figure 3 The adaptive and maladaptive energy matrices

Figure 1 Historical evolution of the clinical classification and

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Factors underlying metabolic alterations in osteoarthritis

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Heat map of targeted therapies in autoimmune diseases

Figure 7 The efficacy of phosphate-binder therapy

Volume 83, Issue 3, Pages (March 2013)

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 4 Antinuclear antibodies and disease activity in SLE

Figure 3 Transcriptome studies performed in the target

Anemia treatment in chronic kidney disease accompanied by diabetes mellitus or congestive heart failure Steven Fishbane, Nobuyuki Miyawaki Kidney International

Figure 2 Shared genetic loci in systemic autoimmune diseases

Figure 1 The burden of chronic kidney disease (CKD)

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Nucleic acid sensors in SLE

Volume 94, Issue 4, Pages (October 2018)

Survival in chronic hypersensitivity pneumonitis (CHP) patients receiving immunosuppressive therapy. a) 5-year survival based on use of immunosuppressive.

ANZDATA Registry Annual Report 2013

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Algorithm for immunosuppressive treatment

Membranous nephropathy: When and how to treat

Figure 3 Statistical approaches for the analysis of metabolomic data

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Multi-hit model for autoimmune diseases

David J. Tunnicliffe, Suetonia C. Palmer

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Glomerular injury in lupus nephritis

Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Potential strategy for belatacept-based

Figure 6 Hypothetical effect of starting therapy for autosomal

Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials Suetonia C. Palmer,

Erratum American Journal of Kidney Diseases

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 1 Treat to target, remission and low disease activity in SLE

Figure 1 The current model of the pathogenesis of SLE

Discussion on spontaneous resolution of chronic hepatitis C virus after withdrawal of immunosuppression Ulf Peter Neumann, Peter Neuhaus Gastroenterology

World Kidney Day 2016: Kidney Disease & Children

Figure 1 Reproductive health in patients with rheumatic diseases

Figure 1 Principles for the diagnosis and management of osteoarthritis

Volume 60, Issue 2, Pages (August 2001)

Nat. Rev. Rheumatol. doi: /nrrheum

Figure 2 Phenotypes of osteoarthritis

Figure 2 Proposed approach to treating myositis-associated interstitial lung disease Figure 2 | Proposed approach to treating myositis-associated interstitial.

Consolidated Standards of Reporting Trials diagram.

A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease S. Susan Hedayati, Venkata Yalamanchili,

Figure 1 Patterns of joint and organ involvement in rheumatic disease

Current induction and maintenance treatment choices for proliferative lupus nephritis. Current induction and maintenance treatment choices for proliferative.

Volume 66, Pages S7-S10 (November 2004)

Nat. Rev. Nephrol. doi: /nrneph

Suggested treatment algorithm for resistant lupus nephritis

Summary of evidence search and selection.

EULAR Lupus Nephritis Trials Network Study Group

Current standard of care treatment protocols for LN induction therapy.

Networks of treatment comparisons for primary outcomes of SLE agents in patients with SLE. The size of the nodes (blue circles) corresponds to the number.

Volume 77, Issue 2, Pages (January 2010)

Presentation transcript:

Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.174 Figure 3 Selection of induction and maintenance therapy for patients with severe proliferative lupus nephritis Figure 3 | Selection of induction and maintenance therapy for patients with severe proliferative lupus nephritis. Multiple disease-related and patient-related factors affect the choice of therapy, among which perhaps the most important are ethnicity, histological class, disease severity and chronicity, renal function at presentation, and previous treatment responses. Although not shown, treatment costs, the patient's age and sex are additional factors that also need to be taken into account. AZA, azathioprine; CKD, chronic kidney disease; CYC, cyclophosphamide; MMF, mycophenolate mofetil; TAC, tacrolimus. Mok, C. C. (2015) Towards new avenues in the management of lupus glomerulonephritis Nat. Rev. Rheumatol. doi:10.1038/nrrheum.2015.174